Biogen FDA approval for latest Alzheimer's drugUnfortunately Roche's Alzheimer's drug didn't get approved even though Roche was looking into using CognICA to test the general population for early Alzheimer's patients who would benefit from it.
Now that Eisai & Biogen got FDA fast track approval today (Jan 6, 2023) for their latest Alzheimer's drug Lecanemab, they will now need a way to be able to test the general population as well for potential early Alzheimer's patients who can benefit from their new Alzheimer's drug that looks much more promising than their last Alzheimer's drug (it got better results in Clinical 3 trials with a lot less controversy).
On Dec 22, 2022, Eisai applied to China to get Lecanemab approved for the Chinese market which is the largest in the world.
I hope CGN is already working on getting CognICA approved for the China market so that Eisai & Biogen can use it to identify early Alzheimer's patients in China.